Overview of studies that include more than 10 FA patients transplanted for MDS or AML
| Ref. . | Period . | Patients, N . | Disease . | Donor type . | Relapse . | Survival . |
|---|---|---|---|---|---|---|
| 46 | 2001-2007 | 11 | 4 Isolated cytogenetic abnormalities, 6 morphological MDS, and 1 AML | 9 MSD, 1 MMRD, and 1 CB | None | 10/11 patients; median FU 46 mo |
| 14 | 1985-2007 | 113 | 54 Isolated cytogenetic abnormalities, 45 morphological MDS, and 14 AML | 82 MSD, 16 URD, and 15 CB | N/A | 55% OS at 5 y; median FU 84 mo (survivors)* |
| 15 | 1972-2010 | 58 | N/A | 29 MSD, 2 other relative, and 27 URD | 11% CI of relapse | 35% OS at 5 y; median FU 49 mo |
| 16 | 1988-2011 | 21 | 8 Morphological MDS, 12 AML, and 1 ALL (6 BRCA2/D1 patients) | 2 MSD, 1 MMRD, 12 MUD, 4 CB, and 2 DCB | 24% CI of relapse (50% for BRCA2 patients) | 33% OS at 5 y; median FU 9.5 y |
| Ref. . | Period . | Patients, N . | Disease . | Donor type . | Relapse . | Survival . |
|---|---|---|---|---|---|---|
| 46 | 2001-2007 | 11 | 4 Isolated cytogenetic abnormalities, 6 morphological MDS, and 1 AML | 9 MSD, 1 MMRD, and 1 CB | None | 10/11 patients; median FU 46 mo |
| 14 | 1985-2007 | 113 | 54 Isolated cytogenetic abnormalities, 45 morphological MDS, and 14 AML | 82 MSD, 16 URD, and 15 CB | N/A | 55% OS at 5 y; median FU 84 mo (survivors)* |
| 15 | 1972-2010 | 58 | N/A | 29 MSD, 2 other relative, and 27 URD | 11% CI of relapse | 35% OS at 5 y; median FU 49 mo |
| 16 | 1988-2011 | 21 | 8 Morphological MDS, 12 AML, and 1 ALL (6 BRCA2/D1 patients) | 2 MSD, 1 MMRD, 12 MUD, 4 CB, and 2 DCB | 24% CI of relapse (50% for BRCA2 patients) | 33% OS at 5 y; median FU 9.5 y |
CI, cumulative incidence; DBC, double CB; MMRD, mismatched related donor; MSD, matched sibling donor; MUD, matched unrelated donor; Ref., reference; URD, unrelated donor.
Better results with matched sibling donor, younger age (≤14 y), and cytogenetic abnormality only.